Page 2493 - Williams Hematology ( PDFDrive )

2464 Index Index 2465

Megaloblastic anemias, etiology and Membrane attack complex (MAC), 572, 572f for alkylating drug toxicity, 330
pathogenesis (Cont.): Membrane folate transporter, 588 for diffuse large B-cell lymphoma, 1629t
folate deficiency, 583, 590. Membrane inhibitor of reactive lysis (MIRL), for malignant histiocytic diseases, 1110
See also Folate deficiency 572 6-Mercaptopurine (6-MP)
hereditary orotic aciduria, 608 Membrane lipids for acute lymphoblastic leukemia, 1505,
inborn errors of cobalamin metabolism, in abetalipoproteinemia, 681 1516
607, 607t erythrocyte, 662 adverse effects, 324, 1519t
inborn errors of folate metabolism, in hereditary spherocytosis, 672–673 for autoimmune hemolytic anemia, 839
607–608 modification, in cell signaling, 251 for Langerhans cell histiocytosis, 1106,
Lesch-Nyhan syndrome, 608 Membrane matrix metalloproteinase 1107
incomplete, 596 leukolysin, 1010 mechanism of action, 323
ineffective erythropoiesis and, 597 Membrane proteins, 662–667, 663t megaloblastic anemia and, 606t
iron deficiency and, 637 classification, 664 pharmacology, 323–324
laboratory features defects. See Erythrocyte membrane resistance to, 319t
blood cells, 594–595, 594f disorders structure, 323f
in body fluids, 597 integral, 664–665 Meropenem, as empiric therapy for
cytokinetics, 597 band 3, 664, 664f infections, 384, 387t
in epithelial cells, 597 glycophorins, 664–665 Mesenchymal cell plasticity, 54–55
marrow, 595, 595f Rh-RhAG group, 665 Mesenchymal stromal cells (MSCs), 449–450,
neutropenia, 994 peripheral, 663t, 665–667 451
with microcytic anemia, 596 actin and actin-binding proteins, 667 MESNA. See Mercaptoethane sulfonate
misdiagnosed as acute leukemia, 597 adducin, 667 (MESNA)
refractory, 608 ankyrin, 666, 666f, 670–671 Messenger RNA. See mRNA (messenger
thiamine-responsive, 608, 652 defects, 670–672, 670t RNA)
Megaloblastic crisis, in hereditary p55, 667, 667f Metabolic syndrome, 5
spherocytosis, 674 protein 4.1R, 666–667, 667f, 678 Metabolism
Megaloblastoid erythropoiesis, 1350f, 1354 protein 4.2, 667 inborn errors. See Inborn errors of
MEK (mitogen-activated extracellular- spectrin. See Spectrin metabolism
regulated kinase), 298, 1016 Memory B cells, 1172 iron deficiency and, 632
Melanesian elliptocytosis. See Southeast Memory stem cells (CD62L+ cells), 411 of red cells, in newborn, 104
Asian ovalocytosis (SAO) Memory T cells, 1182–1183 Metabolites, in erythrocytes, 471t
Melanocyte growth-stimulating activity, 288t aging and, 135–136 Metacentric centromere, 175t
Melanoma in immune cell therapy, 411 Metachromatic leukodystrophy, 439
cellular therapy, 412–413 killer cell immunoglobulin-like receptors Metal ion-dependent adhesion site (MIDAS),
marrow infiltration in, 659f and, 1190 2044–2045, 2044f
Melanoma differentiation-associated 5 Menatetrenone (vitamin K ), 1360 Metamyelocytes
2
(MDA5), 300–301, 302f Mendelian genetics, 147 marrow, 34
MELAS syndrome, 2108 Mendelian susceptibility to mycobacterial maturation, 926f, 940–941, 940f, 941t
MELD (model of end-stage liver disease), disease, 1231 normal values, 32t
2192 Meningococcal disease, 304 structure, 925–926, 927f
Melena, 5, 1987 Meningococcal vaccine, 773 Metformin, megaloblastic anemia and,
Melphalan Menorrhagia, 5–6, 1987, 2007, 2135, 2139 606t
for AL amyloidosis, 1761, 1779–1780 Menstrual bleeding, iron deficiency and, 629 Methemoglobin. See Hemoglobin M
for γ-heavy-chain disease, 1806 Mental retardation, α-thalassemia and, 739, Methemoglobinemia, 789–794
high-dose, before hematopoietic cell 745 clinical features, 791t, 792
transplantation, 331t, 364, 365f MEP (megakaryocyte-erythroid progenitor) definition and history, 789
for Hodgkin lymphoma, 1616 cells, 259, 268 epidemiology, 789
mechanism of action, 329 Meperidine, 767 etiology and pathogenesis, 789–791, 790t,
for myeloma, 1751, 1752t Mephenytoin, drug-related hemolytic anemia 791f, 791t
platelet function and, 2079 and, 824 laboratory features, 792, 793f
Membrane Mepolizumab, 954 treatment and course, 432, 793
basophil, 967t Mer, 1845 Methicillin-resistant Staphylococcus aureus
erythrocyte. See Erythrocyte membrane MER2. See CD151 (MRSA) infections, 384–385
lymphocyte, 1143–1144, 1144t MER2 antigen, RAPH blood group, 2343 Methionine synthesis, 586t, 589–590
mast cell, 967t Mercaptoethane sulfonate (MESNA). See also Methotrexate, 318–321. See also CODOX-M/
platelet. See Platelets CODOX-M/IVAC regimen IVAC regimen

Kaushansky_index_p2393-2506.indd 2464 9/21/15 3:22 PM